iTrack™ is the only illuminated, micron-scale microcatheter designed to viscodilate Schlemm’s canal during MIGS with ABiC™. A standout feature of the iTrack™ is its illuminated tip, which allows you to continually monitor its location during canal circumnavigation.

ABiC WITH iTRACK

SCHEDULE A DEMO

Performed as a standalone procedure or as an adjunct to cataract surgery, ABiC is a new MIGS procedure that can comprehensively restore the natural outflow pathway in glaucoma patients.

Introducing a new comprenhensive MIGS

LEARN MORE

Vitreolysis. Redefining Convention.

Virtually every individual will experience the visual shadows caused by vitreous strands and opacities during their lifetime. Vitreolysis provides an effective outpatient-based treatment for floaters and overcomes many of the risks associated with traditional surgery.

LEARN MORE

SLT. Gentle. Effective Repeatable.

A highly effective approach for first-line glaucoma treatments, as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail, Selective Laser Trabeculoplasty (SLT) stimulates a natural healing response in the eye to manage intraocular pressure.

LEARN MORE

2RT® is a nanosecond laser therapy that stimulates a natural, biological healing response in the eye to treat degenerative retinal disease, including AMD.

For 30 years, Ellex has been at the forefront of ophthalmic innovation, introducing cutting-edge products and technologies for the diagnosis and treatment of eye disease.

Pioneering solutions for eye care since 1985.

For more than 30 years, Ellex has been committed to the fight against blindness. Our vision is to pioneer integrated medical technologies and solutions for the diagnosis and treatment of eye disease.

A Global Outlook.

Over the years, Ellex has evolved from a small scientific laser company to a global leader in medical technologies. Today, more than 30,000 Ellex laser and ultrasound systems are used around the world in the fight against blindness.

3 November 2010

Ellex Secures Additional Distribution Deal with CenterVue

Adelaide, Australia, 3 November 2010: Ellex Medical Lasers Limited (ASX:ELX), a global leader in ophthalmic laser and ultrasound technology, today announced that it has secured a second distribution deal with Italian-based CenterVue to market the DRS retinal camera in the United States. This follows the Company’s recent announcement that it had secured distribution rights for CenterVue’s MAIA™ fundus perimetry system in the United States and Australia.

A high-resolution digital camera, the DRS system uses an automated process to capture high-quality images of the retina with minimal operator involvement.

DRS is expected to open up new market segments for the Company in the United States, and will also broaden the Company’s customer base to include optometrists, in addition to ophthalmologists.

“DRS is a perfect fit for our existing portfolio of retinal treatment lasers, as well as the recently-added MAIA fundus perimetry system. With the addition of the DRS system our customers will now be able to perform all facets of patient diagnosis in the management of retinal disease,” commented Ellex CEO, Simon Luscombe.

Under the terms of the non-exclusive distribution agreement, Ellex will leverage its existing direct sales and distribution channels to sell the DRS retinal camera in the United States.

The Company expects DRS to generate high-volume sales, contributing significantly to increased growth during the 2011 financial year.

“Every optometric and retinal practice needs a retinal camera. Our well-established sales and marketing infrastructure in the United States will enable us to integrate the DRS into our sales mix immediately, and we are confident that this important new product addition will deliver improvements to our bottom line during the current financial year,” said Mr. Luscombe.

The DRS distribution agreement marks another important step in Ellex’s stated diversification strategy, which will see the Company broaden its product portfolio through a number of strategic partnerships and alliances for growth into the $12 billion global ophthalmic market. It will also strengthen the Company’s growing third-party distribution business, which generated revenues of approximately $7 million in the 2010 financial year over and above sales of the Company’s proprietary products and technologies.

DRS will be previewed at the Ellex exhibit #656 during the annual meeting of the American Academy of Optometry (AAO) in San Francisco from Thursday, 17 November 2010.

ABOUT ELLEX

Ellex Medical Lasers Limited (ASX:ELX) is a global leader in the design and manufacture of ophthalmic laser and ultrasound systems used by ophthalmologists to diagnose and treat eye disease. With more than 15,000 systems delivered to the market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan, Germany and Australia, and a network of distribution partners in more than 100 countries. In recent years, Ellex has diversified its product range beyond lasers and ultrasound equipment to include a number of third-party ophthalmic products.

ABOUT DRS

DRS represents the new frontier of non-mydriatic, digital retinal imaging. Featuring fully automated operation, DRS requires minimal operator training. Its compact, ergonomic design and low power flash help ensure patient comfort. The system is operated through an intuitive touch-screen interface, and supports single- or multi- field acquisition protocols. DRS was cleared for marketing in the United States by the US Food and Drug Administration (FDA) on 29 October 2010.

For additional information about the DRS, please visit centervue.com/en/pages/drs

ABOUT CENTERVUE

CenterVue SpA is a profitable, Italian-based medical device manufacturer dedicated to developing new technologies to aid the early detection of many diseases. Collectively, the CenterVue team has more than 90 years’ experience in the ophthalmic industry, and includes an in-house research team.